fbpx

15th Annual Congress on Controversies in Ophthalmology (COPHy 2024)

Find Out More

Eylea (aflibercept

Regeneron

REGENERON ANNOUNCES ENCOURAGING TOPLINE PHASE 2 DATA OF HIGH-DOSE AFLIBERCEPT IN WET AGE-RELATED MACULAR DEGENERATION TARRYTOWN, N.Y., Aug. 24, 2021 /PRNewswire/ — Phase 3 trials in wet AMD and diabetic macular edema…

Newsletter Sign-up

  • This field is for validation purposes and should be left unchanged.